Moneycontrol PRO
HomeNewsBusinessDiageo exits HipBar investment, says alcohol home delivery model will take years to mature

Diageo exits HipBar investment, says alcohol home delivery model will take years to mature

HipBar co-founder Natarajan said that the firm faced some pushback from some pockets of the trade and the state excise department of Karnataka and this matter is still sub-judice.

July 26, 2021 / 11:24 IST
The move comes at a time when more and more states are joining the alcohol home delivery bandwagon. Representative image

The move comes at a time when more and more states are joining the alcohol home delivery bandwagon. Representative image

Diageo has exited from its investment in alcohol home delivery startup HipBar. Diageo invested Rs 27 crore via domestic entity USL in exchange for the stake in the Chennai-based company in 2018.

The UK-based liquor company crore sold its 26 percent stake in HipBar to the startup’s promoter Prasanna Natarajan for Rs 52 lakh, Times of India reported.

The move comes at a time when more and more states are joining the alcohol home delivery bandwagon.

Stating the reason behind the decision, Diageo spokesperson said that, while home delivery had opened up in several states since 2020, it would take some years to mature as a model."

"In addition, the alcobev model is likely to develop quite differently in India to regular e-commerce due to the nature of regulation of this industry," the spokesperson added.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Speaking to TOI, HipBar co-founder Natarajan said that the firm faced some pushback from some pockets of the trade and the state excise department of Karnataka and this matter is still sub-judice.

"HipBar, being an early and solo mover, had to face many regulatory hurdles and challenges to open up home delivery, which it eventually did with states of West Bengal and Odisha. Post COVID-19, the market dynamics have changed and the more established players are also entering this niche space," he added.

Moneycontrol News
first published: Jul 26, 2021 11:24 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347